Gilead Sciences (GILD) Acquisitions (2011 - 2026)

Gilead Sciences has reported Acquisitions for 10 years, with the latest figure at $109.0 million in Q1 2026.

• For the quarter ending Q1 2026, Acquisitions fell 60.07% year-over-year to $109.0 million; the trailing twelve-month figure through Mar 2026 stood at $906.0 million (down 15.33% YoY), and the FY2025 full-year result was $1.1 billion, down 77.89% from the prior year.
• Acquisitions for Q1 2026 stood at $109.0 million, down from $609.0 million in the prior quarter.
• The five-year high for Acquisitions was $4.0 billion in Q1 2024, with the low at $21.0 million in Q2 2025.
• Historically, Acquisitions has averaged $527.5 million across 5 years, with a median of $273.0 million in 2025.
• The largest YoY upside for Acquisitions was 712.0% in 2025 against a maximum downside of 93.25% in 2025.
• Gilead Sciences' Acquisitions stood at $218.0 million in 2022, then gained by 27.98% to $279.0 million in 2023, then sank by 73.12% to $75.0 million in 2024, then surged by 712.0% to $609.0 million in 2025, then sank by 82.1% to $109.0 million in 2026.
• The last three Acquisitions figures came in at $109.0 million (Q1 2026), $609.0 million (Q4 2025), and $167.0 million (Q3 2025), per Business Quant data.